Abstract #3121

Optimized CEST acquisition and analysis for treatment assessment of response to neoadjuvant chemotherapy in triple negative breast cancer

Shu Zhang¹, Abeer H. Abdelhafez², Jong Bum Son³, Benjamin C. Musall³, Mitsuharu Miyoshi⁴, Xinzeng Wang⁵, Ken-Pin Hwang³, Gaiane M. Rauch², Jingfei Ma³, and Mark D. Pagel¹

¹Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, United States, ²Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, United States, ³Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States, ⁴Global MR Applications & Workflow, GE Healthcare Japan, Tokyo, Japan, ⁵Global MR Applications & Workflow, GE Healthcare, Houston, TX, United States

In our ongoing study of 13 completed patients, we compared two saturation power levels (2.0 μT vs. 0.9 μT) and two analysis methods (MTR_asym vs. Lorentzian line fitting) of CEST for assessing treatment response to neoadjuvant chemotherapy of triple-negative breast cancer (TNBC). A consistently decreasing trend of the CEST signals was observed with the longitudinal treatment when a higher saturation power of 2.0 μT was used with the amide MTR_asym analysis method. In contrast, the same trend was observed when a lower saturation power of 0.9 μT was used for the Lorentzian line fitting analysis method.

This abstract and the presentation materials are available to members only; a login is required.

Join Here